Register Free
UK’s Clinical Knowledge Hub • NICE • MHRA • NHS England

Clinical intelligence,
instantly accessible.

Search UK and European guidelines, safety updates, clinical trials, drug mechanisms and CPD resources in one evidence-based platform.

234+ NICE Guidelines
2127+ Clinical Trials
975+ News Articles
Open Education
Browse Guidelines → Explore Drug Science
Safety Alert Filters should be used during the administration of Parenteral Nutrition for patients in all care settings 02 Sep 2026
All Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health Nephrology Haematology
Explore by Specialty All specialties →
Oncology 896 Cardiology / Cardiovascular 417 Respiratory / COPD / Asthma 278 Infectious Disease 142 Gastroenterology 122 Diabetes / Metabolic 115 Neurology 113 Rheumatology 103 Women's Health 98 Mental Health / Psychiatry 87 Dermatology 37 Rare Diseases 18 Men's Health 12 Nephrology 1 Haematology 1
Trial Gastroenterology clinicaltrialsgov

A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

# Summary for UK Clinicians Trial testing linvoseltamab alone or with carfilzomib versus standard treatments in patients with relapsed/refractory myeloma after 1-3 prior therapies.

Phase 3 Recruiting NCT07222761
Start Date
Jan 2026
Est. Completion
May 2029
08 Oct 2026 Read article →
Latest
Trial clinicaltrialsgov
Enlighten Study: The EV-ICD Post Approval Registry
08 Oct 2026
Trial
BEAT-Breast: Trial of DE-iPTV in Patients With Primary Breast Cancer With Brain Metastases Who Are Not Suitable for Stereotactic Radiotherapy.
08 Oct 2026
Clinical Intelligence
Guidelines
View all guidelines →
NICE Oncology
Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy
  • ●Trastuzumab deruxtecan is recommended by NICE as a treatment option for HER2-low…
  • ●Consider trastuzumab deruxtecan specifically in patients with confirmed HER2-low status (IHC 1+…
07 Oct 2026
NICE Neurology
Software with artificial intelligence (AI)-derived algorithms to help interpret electroencephalograms (EEGs) for suspected epilepsy: early-use assessment
  • ●AI-assisted EEG interpretation software can support clinicians in identifying abnormalities suggestive of…
  • ●AI algorithms may help reduce reporting delays and increase consistency in EEG…
01 Oct 2026
NICE
Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is suitable
  • ●Daratumumab with bortezomib, lenalidomide and dexamethasone is recommended as an option for…
  • ●Ensure baseline assessment includes renal function, cardiac status and infection screening before…
30 Sep 2026
Trial Radar
Clinical Trials
Trial collections View all trials →
RECRUITING
Prospective Evaluation of AI-ECG for SHD Detection
AI-ECG-SHD is a multicentre prospective observational diagnostic accuracy study evaluating artificial intelligence-enhanced electrocardiography (AI-ECG) for the detection of structural heart…
Cardiology / Cardiovascular
PHASE1 RECRUITING
A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML
The goal of this study is to evaluate the safety of CHM-029, an investigational oral medicine, and to evaluate its…
Oncology
Active Not Recruiting
Follow-up in Gynecological Cancer Survivors
A cross-sectional prospective study of follow-up in gynecologic cancer patients after primary treatment Conditions: Gynecologic Cancer Lead Sponsor: European Organisation…
Oncology
Drug Science
Molecular Mechanisms
Starter packs Explore mechanisms →
Mechanism Cardiology / Cardiovascular
HMG-CoA Reductase — Statins
• HMG-CoA Reductase — Statins is a clinically relevant Drug Science explainer. • 3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase catalyses the rate-limiting step in the mevalonate pathway — the…
Open explainer →
Mechanism Gastroenterology
S1P Receptor Modulation — MS/IBD
• S1P Receptor Modulation — MS/IBD is a clinically relevant Drug Science explainer. • Sphingosine-1-phosphate (S1P) is a bioactive sphingolipid metabolite generated by sphingosine kinase-mediated phosphorylation of sphingosine,…
Open explainer →
Mechanism Dermatology
BRAF/MEK Pathway — Melanoma
• BRAF/MEK Pathway — Melanoma is a clinically relevant Drug Science explainer. • The MAPK signalling cascade (RAS-RAF-MEK-ERK) transmits extracellular growth signals from receptor tyrosine kinases to the…
Open explainer →
Latest Updates
Clinical News
View all news →
UKHSA Infectious Disease 08 Oct 2026
£33.2m to protect public from future epidemics and pandemics
• Eight new vaccine projects will receive £33.2m funding to develop treatments against high-threat pathogens, enhancing the UK's pandemic preparedness capabilities• Funding focuses on diseases with epidemic and pandemic potential, aiming to reduce global health risks and support international disease prevention efforts• Investment strengthens the UK's position in vaccine development while contributing to worldwide protection against future infectious disease outbreaks
Read article →
UKHSA 08 Oct 2026
Latest UKHSA weekly winter virus surveillance data
Respiratory / COPD / Asthma
UKHSA 08 Oct 2026
Flu levels low at start of season but higher than previous 4 years
Infectious Disease
BBC Health 08 Oct 2026
‘Ominous signs’ of winter pressures as NHS waiting list grows
Respiratory / COPD / Asthma
CPD Accredited
Podcasts & Education
View all podcasts →
Upcoming 0.5 CPD
Drug Interactions: Mechanisms, Red Flags and Practical Management
Dr Anzal Qurbain
Upcoming 0.5 CPD
Polypharmacy and Deprescribing: When Less Is More
Dr Anzal Qurbain
Upcoming 0.5 CPD
Prescribing in Pregnancy: Safe Choices, Teratogens and Risk Communication
Dr Anzal Qurbain
234+Guidelines
2127+Clinical Trials
975+News Articles
15Specialties